HC Wainwright Has Positive Outlook for UNCY FY2029 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Research analysts at HC Wainwright boosted their FY2029 EPS estimates for Unicycive Therapeutics in a research note issued to investors on Thursday, November 13th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $7.99 per share for the year, up from their prior estimate of $7.61. HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share.

Unicycive Therapeutics (NASDAQ:UNCY) last released its earnings results on Wednesday, November 12th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.20.

A number of other research analysts have also commented on the company. Wall Street Zen upgraded Unicycive Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, November 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Unicycive Therapeutics in a research note on Thursday, October 30th. Finally, Benchmark increased their price target on shares of Unicycive Therapeutics to $21.00 and gave the company a “speculative buy” rating in a report on Monday, September 15th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Unicycive Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.33.

Unicycive Therapeutics Price Performance

Shares of NASDAQ UNCY traded up $0.40 during trading hours on Friday, hitting $5.73. 728,058 shares of the company’s stock were exchanged, compared to its average volume of 396,448. The company’s 50-day moving average price is $4.51 and its 200-day moving average price is $5.09. Unicycive Therapeutics has a 1-year low of $3.71 and a 1-year high of $11.00. The stock has a market capitalization of $101.20 million, a price-to-earnings ratio of -1.46 and a beta of 1.87.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Lazard Asset Management LLC acquired a new stake in Unicycive Therapeutics during the second quarter worth $55,000. JPMorgan Chase & Co. lifted its holdings in shares of Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after acquiring an additional 21,525 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at about $512,000. Vanguard Group Inc. boosted its position in shares of Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after acquiring an additional 52,925 shares in the last quarter. Finally, Vivo Capital LLC increased its stake in Unicycive Therapeutics by 14.0% in the first quarter. Vivo Capital LLC now owns 11,370,152 shares of the company’s stock valued at $6,537,000 after acquiring an additional 1,400,000 shares during the period. 40.42% of the stock is owned by institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.